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In the last few years there have been concerted attempts at using the power of the immune system 
as an effective treatment option for cancer. This has become possible since our understanding of the 
workings of the immune system improved. Tumours form because of failure of the organism to 
destroy a rogue, mutated cell in an appropriate way. Once the tumour is formed it can further 
develop when the immune system fails to contain and control it and certain equilibrium is lost in 
favour of the tumour. This is referred to as the immune editing theory. At this point of failure of the 
immune system, tumour growth and progression become possible and tumours develop various 
mechanisms to evade the immune systems surveillance. Therefore, a mechanism to restore the lost 
equilibrium or to tip it in favour of the immune system would be a new modality in anti-cancer 
treatment. The initial approach was to use stimulators of the immune system systemically such as 
interleukin 2 (IL-2) and interferon Gamma (IFNγ) intravenously in patients with metastatic cancers 
including melanoma and renal cancers [1]. A sustained response was shown in 22% of patients with 
metastatic kidney cancer, lasting for over a year. Although this treatment modality was not a 
resounding success, it did highlight an approach that could yield a durable tumour regression in a 
minority of cases. As our understanding of the immune system–tumour interaction further 
developed, new research focused on a specific mechanism in the immune system that seems to be 
exploited by tumours. This is an activation-inhibition mechanism, which controls the extent of 
adaptive immune response to invading organisms or to mutated cancer cells. In healthy individuals, 
this mechanism is a ‘safety’ feature allowing cessation of the immune response once it has 
performed its task. This is controlled by “receptor” molecules at the T-cell surface and their 
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corresponding “ligands” at the surface of the cells interacting with the T-cell, which can be an 
antigen presenting cell or a tumour cell surface. This mechanism is called the immune checkpoint [2] 
(Fig. 1). Cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) are the most 
well-known check points but there are up to 20 others (and counting) [2]. Their main role is to inhibit 
an immune response by blocking the activation of T-cells when those cells are presented with a 
foreign antigen or cancer proteins. This inhibition leads to immune ‘tolerance’ of the presence of 
cancer cells. So the policeman (T cell) is oblivious to the robbery in front of him. Thus an anti-tumour 
treatment strategy to disrupt the immune checkpoints seems to be a valid one.  
In recent years a plethora of various inhibitors in the form of monoclonal antibodies to the check 
point molecules were developed and to date three at least have been approved by the FDA –
ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda). They are anti-CTLA4 and 
anti-PD1 antibodies. At least another eight checkpoint inhibitors are being developed. These agents 
have been shown to have survival benefit in some malignancies and limited benefit in others. 
However, the breakthrough seems to be happening in the treatment of metastatic malignant 
melanomas where immune check point inhibitors treatment may become the standard of care. 
Patients with metastatic malignant melanoma who were treated with ipilimumab had a median 
survival around 11 months, however 22% of patients survived for at least three years with a plateau 
in the survival curve and in a subset of patients up to 10 years [3]. This success has not yet been 
replicated in prostate cancer [4]. In a more recent clinical trial involving melanoma patients who 
progressed, nivolumab showed survival benefit of 72% at one year as compared to 42% with 
dacarbazine [5]. The latest approach is to combine anti-CTLA-4 and anti-PD1 in one treatment 
regime as they are expected to act synergistically to remove the inhibition to the immune response 
and clinical results seem to show survival benefit for combination therapy [6]. Combination of 
different treatment modalities may potentiate the “abscopal effect”, which is seen when local 
radiation therapy can cause regression of tumour distant to the radiation site. This seems to be 
mediated by the immune system and potentiated by check point inhibitors. Up till now check point 
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inhibitors were used in end stage metastatic cancer patients, but recently anti CTLA-4 has been 
trialled in pre–radical cystectomy patients not as a neoadjuvant therapy but rather to monitor 
immune response and surgical safety [2]. It is likely that check point inhibitors will have a place in 
cancer treatment including urological cancers. However this new class of anti-cancer treatment 
comes with a price. The emerging risks and side effect profile of check point inhibitors are 
completely different from those seen with the conventional chemotherapy and radiotherapy. Those 
side effects are related to the activation of the immune system. Although most are not uncommon, 
they can occasionally have devastating effect on the patients. These side effects include 
autoimmune conditions like dermatitis, mild colitis and occasionally hepatitis. A severe form of 
colitis resulting in perforation has been reported. Unfortunately, the rate of adverse effect seems to 
correlate with positive clinical response. A list of some of the side effects is summarised in table 2. 
Treatment is usually with steroids, and clinicians are starting to develop strategies to minimise those 
risks.  
 
The cost of check point inhibitors remains relatively high and a full treatment course of ipilimumab 
costs more than £18000. One dose of Pembrolizumab can costs more than £3500. However, the 
National Institute for Health and Care excellence (NICE) in the UK deemed this to be cost effective 
and approved it for patients with metastatic melanoma that has progressed despite iplimumab 
treatment.  
 
Would the 21st century be the era for immunotherapy? It is still too early to tell. At present it 
remains rather expensive and beyond the means of many cancer patients.  
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Tumour Phase Treatment  n Results Trial.gov 
identifier 
mCRPC 1  Dentritic cell therapy and Ipilimumab 20 Recruiting  NCT02423928 
All advanced 
solid tumours 
1 Various combination of ipilimumab, nivolumab and 
pembrolizumab 
122 Recruiting  NCT02467361 
RCC 3 Nivolumab vs Everolimus 822 Recruiting  NCT01668784 
RCC 3 Atezolizumab (Anti PD-L1) 70 Good safety profile with antitumour 
activity 
NCT01375842 
mCRPC  3 Ipilimumab vs placebo 799 No improvement of survival in 
treatment group 
NCT00861614 
Urothelial  2 Gemcitabine, cisplatin and ipilimumab combinations 36 Recruiting  NCT01524991 
 
Table 1: A selected group of trials of immune checkpoint inhibitors in urological cancers.  
 
The total number of current trials of immune checkpoint inhibitors is 46 for lung, breast, ovarian, 
rectal, prostate, pancreatic, bladder, renal cancers and melanoma 
 
RCC: renal cell carcinoma 
mCRPC: metastatic castrate resistant prostate cancer  
PD-L1: programmed death ligand 1 
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Adverse effects Common  Rare 
 Diarrhea Severe colitis – colonic perforation 
 Pruritus / dermatitis Adrenal insufficiency  
 Rash  Pan Hypopituitarism  
 Colitis  Hepatitis  
 Fatigue Uveitis  
 Decreased appetite Temporal arteritis  
 
Table 2: autoimmune based adverse effects which are associated with the immune check point 
inhibitors treatment. Most are tolerated. Severe ones are rare but can be devastating. Treatment is 
usually with steroids [2, 5, 6].  
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Figure 1: Blocking checkpoint inhibitors with antibodies is the new immunotherapy strategy to 
unlock the T-cell activation and improve anti-tumour immune response.  
 
 
 
